Annovis Bio, Inc. Healthcare | Biotechnology | USA Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Annovis is working on an Alzheimer's drug; but they are NOT trying to remove amyloid plaques (which everyone else is trying to do, and has failed for years). Here's some stuff I copied from their website: We Are Working to REVERSE the Toxic Cascade Plaques, tangles, and Lewy bodies represent the end stage of neurodegeneration. The disease STARTS with impaired axonal transport caused by high-levels of neurotoxic proteins. Neurotoxic proteins reduce axonal transport and cause a TOXIC CASCADE Impaired axonal transport lowers levels of neurotransmitters and neurotrophic proteins leading to nerve cell death. More info at their website https://www.annovisbio.com/
From https://www.biopharmcatalyst.com/news/2021/phase-2-clinical-data-readouts-on-watch-for-2q-2021 ANVS – Annovis Bio Inc. ANVS401 Alzheimer’s disease (AD) and Parkinson’s disease (PD) Phase 2 Phase 2 initial data released March 16, 2021. PD interim data (April timeline missed) and AD data due May. Full data June / July 2021.
This company was formerly named QR Pharma. https://www.globenewswire.com/news-...ma-Adopts-new-Corporate-Name-Annovis-Bio.html “Our new name – Annovis – communicates the change of our technology from inhibiting APP to normalizing axonal flow in neurodegenerative diseases, thereby normalizing homeostasis in the nerve cell,” said Annovis President and Chief Executive Officer, Maria Maccecchini, Ph.D. “Over the past several years, our understanding of the cause of these diseases has evolved, and we now understand that it is the breakdown of information transport that is the ultimate cause of nerve cell degeneration and death. While carrying forward the research QR Pharma pioneered in this field, the new name Annovis connotes this deeper understanding and the organization’s new direction arising from this fundamental science. Annovis has embarked on the development of drugs that normalize the transport of information in the nerve cell and restore homeostasis in the brain by inhibiting the synthesis of neurotoxic proteins. High levels of neurotoxic proteins are linked to cell death and are the underlying cause of the plaques, tangles and Lewy bodies that are the hallmark of these neurodegenerative diseases. “As the newly rebranded Annovis, we will be better represented in the market as a leader in battling these and many other neurodegenerative diseases.”
Will do some researches on it. Yeah unfortunately so far all of these companies have failed on the Alzheimer's drug
So...there's a finding that the original paper which pointed the finger at amyloid plaques as being the foundation of Alzheimer's, is a fraud. Images in that paper were photoshopped. Over 100 Alzheimer's drugs that fight amyloid plaques were created, and failed. Just FYI these guys have instead been fighting Alzheimer's by going after impaired axonal transport.
The stock only trades 75k shares per day, so beware that this is very volatile. The bid/ask spread is wide. Closed yesterday at $10.54, this morning an analyst, HC Wainwright, initiated coverage with a $40 target on it. I'd really like to see more shares getting traded, at least over 200k.
